Core Viewpoint - Barry M. Sine maintains a bullish outlook on TEN Holdings, Inc. due to its high-margin growth potential, strategic corporate synergies, and compelling valuation upside [1][2] Company Overview - TEN Holdings, Inc. is a provider of event planning, production, and broadcasting services, delivering virtual, hybrid, and physical event experiences through its subsidiary, Ten Events [8] Product and Service Offering - TEN Holdings specializes in high-quality event streaming services for large enterprise clients, focusing on mission-critical corporate events where quality and reliability are essential [3] - The Ten Pro SaaS platform aims to maintain premium quality while simplifying operations and reducing costs, targeting gross margins near 90% [4] Strategic Initiatives - The company is undergoing a sales and marketing overhaul to align its go-to-market strategy with the SaaS launch and broader platform transformation, which is expected to accelerate organic revenue growth and operational leverage [5] - An Early Adopter Program launched in July 2025 allows select enterprises to beta-test Ten Pro, shaping its development for scalable, high-margin revenue growth [4][5] Corporate Structure and Synergies - TEN Holdings is approximately 70% owned by a leading Japanese market player in corporate streaming and virtual events, with plans for a merger post-IPO to create a more powerful ecosystem for enterprise communications [6] Growth Potential - With a dual growth strategy through organic SaaS development and inorganic M&A activity, TEN Holdings is positioned as a compelling opportunity in digital enterprise communications, supported by a strong global parent and scalable technology [7]

Core Insights - Xeriant, Inc. has successfully completed its August production run for NEXBOARD™, an eco-friendly composite construction panel, with plans for at least one additional run in September [1][2] - The production run is a significant step towards final certification and commercialization, with the contract manufacturer enhancing production efficiency [2] - NEXBOARD is made primarily from recycled plastic and fiber waste, utilizing nanotechnology for superior resistance to fire, water, mold, insects, and abrasion, making it a viable alternative to traditional building materials [2] Company Overview - Xeriant, Inc. focuses on the discovery, development, and commercialization of advanced materials and disruptive aerospace technologies [5] - The company aims to provide durable, safe, and cost-effective alternatives to conventional construction materials such as drywall and wood [2][5] - Xeriant's advanced materials line is marketed under the DUREVER™ brand, which includes NEXBOARD, designed to replace various construction materials [5] Market Potential - The market for fire protection materials is projected to grow from $37.69 billion in 2025 to $59.9 billion by 2034, driven by increased regulatory focus on building safety and sustainable construction practices [3] - Xeriant's NEXBOARD is strategically positioned to meet the evolving demands of both conventional and smart building markets [3]

Core Insights - The data supports the potential of isaralgagene civaparvovec as a one-time, durable treatment for Fabry disease, offering significant multi-organ clinical benefits compared to current care standards [1][6] - The STAAR study showed a positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks across all patients, which the FDA has agreed will be the primary basis for approval [1][6] - Sangamo plans to submit a Biologics License Application (BLA) in 2026 under the Accelerated Approval pathway [1][6] Efficacy - The STAAR study included 32 dosed patients with a positive mean annualized eGFR slope of 1.965 mL/min/1.73m/year at 52 weeks, which is favorable compared to approved Fabry treatments [4] - At Week 104, a mean annualized eGFR slope of 1.747 mL/min/1.73m/year was observed for 19 patients [4] - Stable cardiac function was maintained over at least one year, with various cardiac metrics remaining stable [4] Safety - Isaralgagene civaparvovec demonstrated a favorable safety and tolerability profile, with most adverse events being grade 1-2 [12] - The most common treatment-emergent adverse events included pyrexia (60.6%), COVID-19 (36.4%), headache (30.3%), and nasopharyngitis (33.3%) [12] - All treatment-emergent adverse events resolved with clinical management, and there were no safety-related study discontinuations or deaths [12] Regulatory Designations - Isaralgagene civaparvovec has received Orphan Drug, Fast Track, and RMAT designations from the FDA, as well as Orphan Medicinal Product designation from the European Medicines Agency [8] - The company is preparing for BLA submission while engaging in business development for potential commercialization [8] Study Design - The Phase 1/2 STAAR study is a global open-label, single-dose, dose-ranging, multicenter clinical study designed to evaluate isaralgagene civaparvovec in Fabry disease patients [10] - The study enrolled male and female patients, with a median age of 42 and a median follow-up duration of 24 months [7] Quality of Life Improvements - Statistically significant improvements in quality of life scores were observed, including role-physical (+14.8), vitality (+9.6), and bodily pain (+9.0) at week 52 compared to baseline [12] - Improvements in disease severity were reported in the Mainz Severity Score Index, with 22 patients showing total score improvements at 12 months [12]

Stellantis CEO Antonio Filosa to Participate in Kepler Cheuvreux Autumn Conference 2025 AMSTERDAM, September 4, 2025 – Stellantis CEO Antonio Filosa will participate in a fireside chat on Thursday, September 11, 2025, from 3 p.m. to 3:45 p.m. CEST / 9 a.m. to 9:45 a.m. EDT at Kepler Cheuvreux Autumn Conference 2025. To watch the live session, visit the following Company Webcast link:https://stellantis.engagestream.companywebcast.com/2025-09-11_fireside-chat Details for watching the fireside chat are also ...

Core Insights - Boost Mobile is launching the Samsung Galaxy S25 FE, priced at $199 for new customers who switch their number and sign up for the Unlimited Premium plan [2] - The Galaxy S25 FE is designed to provide a premium experience with advanced features, including a stunning display and AI capabilities [2] Device Highlights - The Galaxy S25 FE features a 6.7" FHD+ Dynamic AMOLED 2X display with a 120Hz refresh rate, offering clear viewing and smooth scrolling [5] - It includes a triple rear camera system and a 12MP selfie camera, enhanced by the Pro Visual Engine for high-quality photos and videos [5] - The device is powered by a 4,900mAh battery, supporting 45W Super Fast Charging 2.0 for quick recharging [5] - Built for durability, the Galaxy S25 FE has an Armor Aluminum 2 frame, Gorilla Glass Victus+, and is IP68 certified for water and dust resistance [5] - AI features include Gemini Live for real-time assistance and Generative Edit for editing photos and audio [5] Company Overview - Boost Mobile offers flexible wireless plans starting at $25/month, with no annual contracts and a 30-day money-back guarantee [5] - The company is a brand under EchoStar Corporation, which is publicly traded on NASDAQ [5]

RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced that management will be participating in three upcoming Fall conferences. The Tharimmune team will present new results at the American College of Gastroenterology (ACG) Annual Scientific Meeting, being held October 24-29, 2025 at the Phoenix Convention Cente ...

Core Insights - EUDA Health Holdings Limited has secured distribution rights for T-cell immunotherapies in Malaysia from Shenzhen Inno Immune Co. Ltd, marking a significant expansion into advanced cell therapy [1][2] - The T-cell immunotherapy package will be priced at USD 8,000 per treatment, significantly lower than traditional costs in the region, making it more accessible [4] - This partnership is part of EUDA's strategy to diversify its healthcare portfolio and focus on regenerative and longevity medicine, addressing the healthcare needs of an aging population in Asia [5][6] Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to transform healthcare from reactive treatment to proactive, longevity-focused care [6] - The company aims to address the healthcare needs of over 1.8 billion people in the region, where more than 30% of the population is aging rapidly [6] - EUDA also operates a property management business in Singapore, further diversifying its operations [6] Strategic Partnerships - The agreement with Shenzhen Inno is facilitated by Guangdong Key Lock Health Management Co., Ltd, which has a long-term strategic partnership with both EUDA and Shenzhen Inno [3] - This partnership is expected to enhance EUDA's offerings in immune-enhancing therapies, leveraging Shenzhen Inno's scientific and institutional backing [5][8]

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSXV: EMO) (the “Company” or “Emerita”) announces that it has entered into an amended credit agreement (the “Loan Agreement”) with Nebari Natural Resources Credit Fund II, LP (the “Lender” or “Nebari”) pursuant to which a fourth tranche of USD$35,000,000 will be m ...

MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, and Catalent®, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, announced a strategic partnership redefining how investigational medicinal products (IMPs) are delivered directly to patients’ homes for clinical research. Through this collaboration, Catalent supports Science 37’s Direct-to-Patient Clinical Trial Site m ...

Raise anchored by marquee investors, including leading family offices and institutional investors in India.Values Roadzen’s India Subsidiary, contributing less than 60% of global revenues, at approximately a 25% premium to the Nasdaq-listed parent company’s market capitalization.Proceeds are anticipated to accelerate India growth, drive technology acceleration for the global business, and reinforce Roadzen’s AI leadership – including DrivebuddyAI and core business lines – with 50%+ revenue CAGR expected for ...